In a small trial across ten U.S. research sites, a novel HIV vaccine candidate has shown a result that has eluded scientists ...

The mRNA Therapeutics market is expanding due to advancements in drug development, personalized medicine, and delivery technologies. Opportunities arise from the technology's success in vaccines and ...

HHS Secretary Robert F. Kennedy Jr. used discredited and misrepresented studies to justify canceling research into ...

Six months into Donald Trump’s second term, his administration is at war with the federal judiciary, evading court orders ...

We may be a step closer to a highly effective mRNA vaccine against HIV, but tests so far reveal that the approach can cause ...

The government has canceled nearly $500 million in research grants into the revolutionary technology, which experts believe ...

Scientists used a mRNA-based vaccine to reliably trigger antibodies that block HIV infection in people and monkeys ...

The top public health officials during Trump's first term praised mRNA vaccines. In the second term, officials seem to be retreating from them.

Results from early-stage trial show that 80% of participants who received one of two HIV vaccine candidates produced antibodies against viral proteins.

Robert F. Kennedy Jr. has announced that his department will end funding for a series of mRNA-based vaccines aimed at ...

Adams, who served as surgeon general during the first Trump administration, said Kennedy's assertions about the efficacy of ...

Researchers will monitor 56 HIV-negative adults for six months in the Phase 1 clinical trial, typically the first step in a long road to study the safety and efficacy of a vaccine.